- Home
- SIG vs RCUS Comparison
SIG vs RCUS Comparison
Compare SIG & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIG | RCUS |
|---|---|---|
| Founded | 1950 | 2015 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SIG | RCUS |
|---|---|---|
| Price | $100.26 | $24.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $111.14 | $31.90 |
| AVG Volume (30 Days) | 754.3K | ★ 1.1M |
| Earning Date | 06-02-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 974.07 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $6,247,100,000.00 | $247,000,000.00 |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $1.71 | $45.62 |
| P/E Ratio | $131.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $71.62 | $11.30 |
| 52 Week High | $110.20 | $31.74 |
Technical Indicators
Market Signals| Indicator | SIG | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 33.18 |
| Support Level | $80.87 | $25.94 |
| Resistance Level | $100.46 | $26.43 |
| Average True Range (ATR) | 3.47 | 1.22 |
| MACD | 1.85 | -0.38 |
| Stochastic Oscillator | 77.54 | 0.00 |
Price Performance
Historical ComparisonAbout SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.